◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CDNA

CareDx Inc (CDNA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-09-04

CareDx Inc (CDNA) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Brisbane, United States with about 761 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, CDNA reported $380M in revenue and ($21M) in net income.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

Interactive charts & full statements → Open the CDNA valuation workbench →

CDNA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$458M	$380M	$334M	$280M	$322M	$296M	$192M	$127M	$77M	$48M	$41M	$28M	$27M	$22M	$20M
Gross Profit	$323M	$257M	$224M	$178M	$210M	$199M	$129M	$82M	$44M	$27M	$20M	$18M	$19M	$13M	$13M
Gross Margin %	70.6%	67.5%	67.2%	63.6%	65.1%	67.1%	67.2%	64.2%	56.9%	55.8%	48.0%	63.5%	68.7%	58.9%	61.2%
Operating Income (EBIT)	($4M)	($25M)	$41M	($203M)	($77M)	($30M)	($23M)	($25M)	($16M)	($20M)	($37M)	($12M)	$1M	($1M)	($2M)
Operating Margin %	-0.9%	-6.6%	12.2%	-72.5%	-24.0%	-10.0%	-11.7%	-19.3%	-20.3%	-42.0%	-91.9%	-42.4%	4.6%	-3.9%	-11.5%
Net Income	$111M	($21M)	$53M	($190M)	($77M)	($31M)	($19M)	($22M)	($47M)	($55M)	($39M)	($14M)	$1M	($4M)	($5M)
Net Margin %	24.2%	-5.6%	15.7%	-67.9%	-23.8%	-10.3%	-9.7%	-17.3%	-61.1%	-114.8%	-97.1%	-48.7%	2.9%	-16.0%	-24.7%
EBITDA	$16M	($5M)	($34M)	($85M)	($60M)	($20M)	($8M)	($17M)	($11M)	($15M)	($18M)	($12M)	$1M	$0M	($1M)
Earnings Per Share (EPS)	$2.07	$-0.40	$0.93	$-3.54	$-1.44	$-0.59	$-0.40	$-0.52	$-1.31	$-2.38	$-2.39	$-1.16	$0.08	$-0.48	$-0.69
Shares Outstanding (M)	53M	53M	57M	54M	53M	52M	46M	42M	36M	23M	16M	12M	9M	7M	7M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CDNA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$132M	$118M	$108M	$100M	$87M	$85M	$87M	$83M
Gross Profit	$97M	$84M	$73M	$69M	$58M	$56M	$58M	$55M
Gross Margin %	73.5%	71.4%	67.2%	69.4%	66.9%	66.5%	67.5%	66.7%
Operating Income (EBIT)	$0M	$2M	($6M)	$0M	($11M)	($8M)	($12M)	($10M)
Operating Margin %	0.2%	1.5%	-5.6%	-0.2%	-12.4%	-9.5%	-13.8%	-12.7%
Net Income	$111M	$3M	($4M)	$2M	($9M)	($10M)	$78M	($7M)
Net Margin %	83.9%	2.4%	-3.8%	1.7%	-9.9%	-12.2%	90.1%	-8.9%
EBITDA	$4M	$7M	($1M)	$5M	($6M)	($3M)	($7M)	($2M)
Earnings Per Share (EPS)	$2.07	$0.05	$-0.08	$0.03	$-0.16	$-0.19	$1.34	$-0.14
Shares Outstanding (M)	53M	53M	51M	54M	54M	55M	58M	53M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CDNA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	$94M	$42M	$38M	($18M)	($25M)	($19M)	$33M	($3M)	($4M)	($14M)	($17M)	($10M)	($3M)	($1M)	($2M)
Capital Expenditures (CapEx)	$9M	$6M	$6M	$9M	$24M	$20M	$10M	$3M	$7M	$0M	$1M	$1M	$1M	$0M	$0M
Free Cash Flow (FCF)	$85M	$36M	$32M	($28M)	($50M)	($40M)	$23M	($6M)	($11M)	($14M)	($17M)	($11M)	($4M)	($1M)	($2M)
FCF Margin %	18.6%	9.5%	9.5%	-9.9%	-15.4%	-13.3%	12.0%	-4.8%	-14.7%	-30.0%	-42.0%	-38.9%	-14.9%	-2.9%	-9.4%
Dividends Paid	—	—	—	—	—	$2M	$1M	$4M	$27M	$0M	$0M	$0M	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CDNA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$31M	$4M	$21M	$37M	$10M	($27M)	$22M	$13M
Capital Expenditures (CapEx)	$2M	$4M	$2M	$1M	$1M	$2M	$2M	$2M
Free Cash Flow (FCF)	$29M	$1M	$20M	$36M	$9M	($28M)	$20M	$11M
FCF Margin %	21.8%	0.4%	18.2%	36.0%	10.2%	-33.3%	23.5%	13.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CDNA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$533M	$413M	$491M	$467M	$543M	$567M	$369M	$152M	$131M	$84M	$77M	$56M	$61M	$10M	$10M
Cash & Cash Equivalents	$374M	$65M	$115M	$82M	$90M	$348M	$135M	$38M	$65M	$17M	$17M	$30M	$36M	$5M	$6M
Total Liabilities	$107M	$110M	$113M	$205M	$112M	$101M	$91M	$53M	$35M	$90M	$57M	$26M	$20M	$161M	$157M
Total Debt (Short + Long-Term)	$6M	$7M	$6M	$6M	$6M	$4M	$2M	$3M	$0M	$34M	$24M	$16M	$11M	$15M	$15M
Total Shareholders' Equity	$426M	$303M	$378M	$261M	$431M	$466M	$278M	$99M	$96M	($6M)	$19M	$29M	$41M	($151M)	($147M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CDNA viewer.

Other Companies in DIAGNOSTICS & RESEARCH

ADPT · Adaptive Biotechnologies Corp — $5 billion
GRAL · GRAIL, LLC — $4 billion
VCYT · Veracyte Inc — $3 billion
WGS · GeneDx Holdings Corp. — $3 billion
FRNM · Freenome, Inc. Common stock — $2 billion
PSNL · Personalis Inc — $2 billion
OPK · Opko Health Inc — $1 billion
CSTL · Castle Biosciences Inc — $1 billion

← CDLX All “C” companies CDNG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.